At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
SXTP 60 degrees pharmaceuticals, Inc.
Not Yet Opened 10-20 16:00:00 EDT
0.9222
+0.0949
+11.47%
盘后0.9061
-0.0161-1.75%
17:41 EDT
High0.9999Low0.8115Vol34.28K
Open0.8263D1 Closing0.8273Amplitude22.77%
Mkt Cap3.24MTradable Cap1.63MTotal Shares3.52M
T/O30.17KT/O Rate1.93%Tradable Shares1.77M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

60 Degrees highlights interim tafenoquine data, caps enrollment
TIPRANKS  ·  10-06
60 Degrees highlights interim tafenoquine data, caps enrollment
60 Degrees Pharmaceuticals - to Unblind Severe Babesiosis Study; Results Expected January 2027
THOMSON REUTERS  ·  10-06
60 Degrees Pharmaceuticals - to Unblind Severe Babesiosis Study; Results Expected January 2027
60 Degrees Pharmaceuticals Plans January 2027 Hospitalized Babesiosis Data Readout; Will Seek Pre-Snda Meeting with FDA
THOMSON REUTERS  ·  10-06
60 Degrees Pharmaceuticals Plans January 2027 Hospitalized Babesiosis Data Readout; Will Seek Pre-Snda Meeting with FDA
60 Degrees Pharmaceuticals Plans January 2027 Hospitalized Babesiosis Data Readout; Will Seek Pre-sNDA Meeting with FDA
GlobeNewswire  ·  10-06
60 Degrees Pharmaceuticals Plans January 2027 Hospitalized Babesiosis Data Readout; Will Seek Pre-sNDA Meeting with FDA
60 Degrees Pharmaceuticals Announces Date for Hospitalized Babesiosis Study Interim Data Release and Key Opinion Leader Webinar
GlobeNewswire  ·  10-01
60 Degrees Pharmaceuticals Announces Date for Hospitalized Babesiosis Study Interim Data Release and Key Opinion Leader Webinar
60 Degrees Advances Babesiosis Treatment With FDA Submission
TIPRANKS  ·  09-15
60 Degrees Advances Babesiosis Treatment With FDA Submission
60 Degrees Pharmaceuticals - Target Supplemental Nda Submission March-April 2027 - SEC Filing
THOMSON REUTERS  ·  09-15
60 Degrees Pharmaceuticals - Target Supplemental Nda Submission March-April 2027 - SEC Filing
60 Degrees Pharmaceuticals - Submits Statement of Interest to FDA Requesting Commissioner's National Priority Voucher for Arakoda - SEC Filing
THOMSON REUTERS  ·  09-15
60 Degrees Pharmaceuticals - Submits Statement of Interest to FDA Requesting Commissioner's National Priority Voucher for Arakoda - SEC Filing
60 Degrees Pharmaceuticals Updates Strategy for Tick-Borne Diseases
TIPRANKS  ·  09-09
60 Degrees Pharmaceuticals Updates Strategy for Tick-Borne Diseases
60 Degrees Pharmaceuticals Announces Participation in H.C. Wainwright 28th Annual Global Investment Conference
GlobeNewswire  ·  09-03
60 Degrees Pharmaceuticals Announces Participation in H.C. Wainwright 28th Annual Global Investment Conference
Analysts’ Opinions Are Mixed on These Healthcare Stocks: OmniAb (OABI), Bicycle Therapeutics (BCYC) and 60 Degrees Pharmaceuticals, Inc. (SXTP)
TIPRANKS  ·  08-17
Analysts’ Opinions Are Mixed on These Healthcare Stocks: OmniAb (OABI), Bicycle Therapeutics (BCYC) and 60 Degrees Pharmaceuticals, Inc. (SXTP)
60 Degrees Pharmaceuticals Q2 EPS USD -0.9
THOMSON REUTERS  ·  08-15
60 Degrees Pharmaceuticals Q2 EPS USD -0.9
60 Degrees Pharmaceuticals Q2 Operating Expenses USD 2.33 Million
THOMSON REUTERS  ·  08-15
60 Degrees Pharmaceuticals Q2 Operating Expenses USD 2.33 Million
Press Release: 60 Degrees Pharmaceuticals Announces Second Quarter 2026 Results
Dow Jones  ·  08-15
Press Release: 60 Degrees Pharmaceuticals Announces Second Quarter 2026 Results
60 Degrees Pharma Q2 FY26 Net Loss Widens 30.6% to $2.26 Million; Revenue More than Doubles to $207,898
Reuters  ·  08-15
60 Degrees Pharma Q2 FY26 Net Loss Widens 30.6% to $2.26 Million; Revenue More than Doubles to $207,898
60 Degrees Pharmaceuticals Holds Annual Shareholder Meeting
Reuters  ·  08-07
60 Degrees Pharmaceuticals Holds Annual Shareholder Meeting
60 Degrees Pharmaceuticals Issues Series A, Series B Warrants Exercisable at $1.49 in $1 Million Private Placement
Reuters  ·  08-05
60 Degrees Pharmaceuticals Issues Series A, Series B Warrants Exercisable at $1.49 in $1 Million Private Placement
60 Degrees Pharmaceuticals Completes Private Placement to Raise Capital
TIPRANKS  ·  08-05
60 Degrees Pharmaceuticals Completes Private Placement to Raise Capital
60 Degrees Pharmaceuticals to sell shares and warrants in private placement
TIPRANKS  ·  07-31
60 Degrees Pharmaceuticals to sell shares and warrants in private placement
60 Degrees Pharmaceuticals, Inc. Announces Private Placement Priced at-the-Market Under NASDAQ Rules
THOMSON REUTERS  ·  07-31
60 Degrees Pharmaceuticals, Inc. Announces Private Placement Priced at-the-Market Under NASDAQ Rules
No data available

Introduction

Company Name.
60 degrees pharmaceuticals, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue. 60 Degrees Pharmaceuticals, Inc. was founded in 2010 and is based in Washington, District Of Columbia.
Issue price:
--